Logo
x

Search category

Subscribe Now

Gloria Biosciences

Gloria Biosciences’ Zimberelimab Receives NMPA’s Approval for Recurrent or Metastatic Cervical Cancer in China

Gloria Biosciences’ Zimberelimab Receives NMPA’s Approval for Recurrent or Metastatic Cervical Cancer in China

  • September 8, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.